Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Phase 1

Completed

• Conditions: Graft Versus Host Disease

• Registration Number: NCT00056875
• Lead Sponsor: University of Michigan

Brief Summary

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Detailed Description

Completion date provided represents the completion date of the grant per OOPD records

Study Timeline

• Study Start: 2002-09
• Study First Submitted: 2003-03-25
• Study First Submitted QC: 2003-03-26
• Study First Posted: 2003-03-27
• Study Completion: 2005-06
• Status Verified: 2006-02
• Last Update Submitted: 2015-03-24
• Last Update Posted: 2015-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

University of Michigan Cancer Center; 🇺🇸 Ann Arbor, Michigan, United States